Edition:
United Kingdom

Neothetics Inc (NEOT.OQ)

NEOT.OQ on NASDAQ Stock Exchange Capital Market

1.64USD
15 Dec 2017
Change (% chg)

$0.01 (+0.61%)
Prev Close
$1.63
Open
$1.66
Day's High
$1.79
Day's Low
$1.64
Volume
132,406
Avg. Vol
260,516
52-wk High
$2.60
52-wk Low
$0.30

Summary

Name Age Since Current Position

Susan Knudson

53 2014 Chief Financial Officer

Maria Feldman

52 2016 Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance

Kim Kamdar

49 2011 Lead Independent Director

Martha Demski

64 2014 Independent Director

Maxim Gorbachev

41 2014 Independent Director

Jeffrey Nugent

70 2015 Independent Director

Biographies

Name Description

Susan Knudson

Ms. Susan A. Knudson is the Chief Financial Officer of Neothetics, Inc. Ms. Knudson previously served as our Vice President of Finance and Administration since February 2009. Prior to joining Neothetics, Ms. Knudson served as Senior Director of Finance and Administration at Avera Pharmaceuticals from May 2002 to January 2009. Prior to May 2002, Ms. Knudson served as Director of Finance and Administration at MD Edge, Inc., a medical communications company, from October 2000 to April 2002. Prior to joining MD Edge, Ms. Knudson served as Assistant Director of Accounting at Isis Pharmaceuticals from April 2000 to October 2000. Ms. Knudson has also held senior positions at CombiChem, General Atomics and Deloitte & Touche. Ms. Knudson holds a B.A. in Accounting from the University of San Diego.

Maria Feldman

Ms. Maria Feldman is Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance of the Company. Ms. Feldman served as Senior Director of Clinical Research and Operations from March 2014 to February 2016 and consultant to Neothetics from December 2011 to February 2016. Prior to joining, Ms. Feldman was Senior Director of Regulatory Affairs at MediciNova, Inc., from 2004 to 2011. Prior to joining MediciNova, Inc., Ms. Feldman assumed various roles of increasing responsibility within Development Chemistry, Quality and Regulatory Affairs at Isis Pharmaceuticals, Inc., from 1991 to 2004. Ms. Feldman holds a B.A. in Chemistry from St. Olaf College.

Kim Kamdar

Dr. Kim P. Kamdar, Ph.D., serves as Lead Independent Director of Neothetics, Inc. Dr. Kamdar has served as a member of our Board of Directors since April 2011. Dr. Kamdar is a managing member of Domain Associates, LLC, a life sciences venture capital firm, which she joined in 2005. Prior to joining Domain, Dr. Kamdar served as a Kauffman Fellow with MPM Capital. Prior to joining MPM Capital, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. Dr. Kamdar currently serves on the Board of Directors of several private and public companies, including Epic Sciences, Inc., Obalon Therapeutics, Omniome, Inc., ROX Medical, SalveoDx, Sera Prognostics, Singular Genomics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. Dr. Kamdar received her B.A. in genetics and cell biology from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University.

Martha Demski

Ms. Martha J. Demski serves as Independent Director of Neothetics, Inc. Since August 2011, Ms. Demski has served as a member of our Board of Directors since July 2014. Since August 2011, Ms. Demski has served as Senior Vice President and Chief Financial Officer of Ajinomoto Althea, Inc. (formerly Althea Technologies, Inc.), a fully-integrated contract development and manufacturing organization. From July 2008 to December 2010, Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center, or SKCC, a non-profit corporation that was engaged in biomedical research which voluntarily filed for Chapter 11 bankruptcy in 2009. Ms. Demski currently serves on the Board of Directors and chairs the audit committee of Adamas Pharmaceuticals, Inc., a publicly traded biotech company. Ms. Demski also serves as a member of the board, chair of the audit committee and member of the nominating and governance committee of Chimerix, Inc., a publicly traded biotech company. Additionally, Ms. Demski previously served as Vice President and Chief Financial Officer of Vical Incorporated, a biopharmaceutical company, and has over 13 years of banking experience with Bank of America and U.S. Trust. She is a National Association of Corporate Directors Board Governance Fellow. Ms. Demski earned a B.A. from Michigan State University and M.B.A. from The University of Chicago Booth School of Business with concentrations in accounting and finance.

Maxim Gorbachev

Mr. Maxim Gorbachev serves as Independent Director of Neothetics, Inc. Mr. Gorbachev has served as a member of our Board of Directors since July 2014. Mr. Gorbachev is a partner at RMI Partners, LLC, or RMI Partners, the management company of RusnanoMedInvest, LLC, or RMI LLC, a Russian-based life sciences venture capital firm, founded by RUSNANO State Corporation, which he joined in March 2013. Prior to joining RMI Partners, from September 2012 to March 2013, Mr. Gorbachev served as Associate Director, Business Planning at JSC Sukhoi Civil Aircraft, an aerospace company. Prior to joining JSC Sukhoi Civil Aircraft, from March 2012 to September 2012, Mr. Gorbachev acted as a consultant to various companies. From July 2009 to February 2012, Mr. Gorbachev served as Director of Finance and Administration at UCB Pharma LLC, a pharmaceuticals company. Prior to joining UCB Pharma, Mr. Gorbachev served as Investment Manager at Sminex, a Moscow-based private equity fund. Mr. Gorbachev currently serves on the boards of several of RMI LLC’s portfolio companies, including Miramar Labs, Atlas Genetics and Celtaxsys. Mr. Gorbachev earned a M.S. in applied mathematics from Lomonosov Moscow State University, a M.S. in Financial Management from Financial University under the Government of the Russian Federation and an M.B.A. from Vlerick Business School.

Jeffrey Nugent

Mr. Jeffrey M. Nugent is Independent Director of Neothetics, Inc. Mr. Nugent has served as a director of the Company since September 2015. Since November 2015, Mr. Nugent has served as Chairman and Chief Executive Officer of Sientra. Mr. Nugent had served as a director to Sientra since July 2014. Mr. Nugent's prior experiences include serving as CEO and Worldwide President of Neutrogena from 1995 to 1999. Following Neutrogena, he became President and CEO of Revlon from 1999 to 2002. Prior to joining Revlon, Mr. Nugent was Founder, President and CEO of Precision Dermatology, a multi - channel dermatology and skin care company he established in 2010 and was acquired by Valeant Pharmaceuticals in 2013. Mr. Nugent most recently served as President, CEO and member of the Board of Directors of Biolase (Nasdaq) between 2014 and 2015. Mr. Nugent holds an MBA in Finance and Marketing from Loyola University of Chicago and BS in Mathematics from St. Joseph's College.

Basic Compensation

Name Fiscal Year Total

Susan Knudson

413,640

Maria Feldman

--

Kim Kamdar

--

Martha Demski

--

Maxim Gorbachev

--

Jeffrey Nugent

--
As Of  31 Dec 2015

Options Compensation